The arrival of Retatrutide in the UK is creating significant excitement within the obesity community. This innovative dual agonist – targeting both GLP-1 and GIP – suggests a significantly new solution to combating excess weight . Until recently, options have been restricted for many, and Retatrutide represents a promising opportunity for indiv